AS-tDR-007333 can enhance the proliferation of NSCLC cells by activating the interaction between HSPB1 and MED29, as well as by interacting with ELK4 to modulate the transcription of the MED29 promoter. This evidence concerns the gene MED29 and non-small cell lung carcinoma.